Avanos Medical Stock EBITDA

AVNS Stock

USD 14.62 0.01 0.07%

Avanos Medical fundamentals help investors to digest information that contributes to Avanos Medical's financial success or failures. It also enables traders to predict the movement of Avanos Stock. The fundamental analysis module provides a way to measure Avanos Medical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Avanos Medical stock.

		Last Reported	Projected for Next Year
	EBITDA	-345.6 M	-328.3 M

EBITDA is likely to gain to about (328.3 M) in 2025.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Avanos Medical Company EBITDA Analysis

Avanos Medical's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Avanos Medical EBITDA

(345.6 M)

Most of Avanos Medical's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Avanos Medical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Avanos EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Avanos Medical is extremely important. It helps to project a fair market value of Avanos Stock properly, considering its historical fundamentals such as EBITDA. Since Avanos Medical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Avanos Medical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Avanos Medical's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Good Will	Total Liab	Deferred Long Term Liab	Short Long Term Debt	Total Current Assets	Treasury Stock	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Debt	Long Term Debt Total	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.93	-0.03	0.0	0.79	0.85	0.95	0.95	0.76	0.12	0.2	0.82	0.08	0.23	0.64	0.83	0.88	0.25	0.37	0.07	-0.17	0.17	0.09	0.16
Total Stockholder Equity	0.93		0.01	0.1	0.56	0.71	0.81	0.94	0.46	-0.06	-0.05	0.65	-0.01	0.0	0.67	0.77	0.86	-0.05	0.04	-0.06	-0.1	0.07	-0.03	0.14
Net Tangible Assets	-0.03	0.01		-0.5	-0.1	-0.47	-0.01	-0.24	-0.1	0.15	-0.41	0.24	-0.68	-0.41	0.41	0.36	-0.33	-0.34	-0.31	-0.85	0.54	-0.64	-0.78	-0.15
Retained Earnings	0.0	0.1	-0.5		-0.07	0.19	-0.15	0.16	-0.17	-0.71	-0.25	-0.16	0.64	-0.24	-0.3	-0.5	0.03	-0.08	-0.11	0.56	-0.8	0.78	0.62	0.69
Accounts Payable	0.79	0.56	-0.1	-0.07		0.83	0.83	0.68	0.91	0.21	0.5	0.86	0.35	0.49	0.3	0.6	0.64	0.6	0.55	0.3	-0.3	0.33	0.35	0.14
Long Term Debt	0.85	0.71	-0.47	0.19	0.83		0.83	0.85	0.79	0.05	0.44	0.71	0.5	0.46	0.23	0.5	0.83	0.57	0.55	0.57	-0.44	0.51	0.57	0.19
Net Receivables	0.95	0.81	-0.01	-0.15	0.83	0.83		0.87	0.85	0.27	0.34	0.84	0.06	0.36	0.57	0.85	0.84	0.36	0.54	0.06	-0.09	0.11	0.07	0.11
Good Will	0.95	0.94	-0.24	0.16	0.68	0.85	0.87		0.64	-0.03	0.16	0.64	0.16	0.2	0.53	0.71	0.95	0.13	0.31	0.16	-0.25	0.23	0.18	0.17
Total Liab	0.76	0.46	-0.1	-0.17	0.91	0.79	0.85	0.64		0.39	0.56	0.83	0.21	0.55	0.35	0.61	0.59	0.67	0.81	0.26	-0.22	0.28	0.28	0.13
Deferred Long Term Liab	0.12	-0.06	0.15	-0.71	0.21	0.05	0.27	-0.03	0.39		0.57	0.24	-0.48	0.56	0.4	0.43	0.09	0.43	0.44	-0.22	0.47	-0.35	-0.29	-0.22
Short Long Term Debt	0.2	-0.05	-0.41	-0.25	0.5	0.44	0.34	0.16	0.56	0.57		0.21	0.3	1.0	-0.07	0.14	0.36	0.8	0.65	0.38	-0.26	0.32	0.37	0.13
Total Current Assets	0.82	0.65	0.24	-0.16	0.86	0.71	0.84	0.64	0.83	0.24	0.21		0.08	0.21	0.51	0.72	0.52	0.49	0.44	0.07	-0.11	0.15	0.12	0.12
Treasury Stock	0.08	-0.01	-0.68	0.64	0.35	0.5	0.06	0.16	0.21	-0.48	0.3	0.08		0.29	-0.55	-0.39	0.17	0.47	0.23	0.87	-0.79	0.84	0.91	0.42
Short Term Debt	0.23	0.0	-0.41	-0.24	0.49	0.46	0.36	0.2	0.55	0.56	1.0	0.21	0.29		-0.04	0.17	0.4	0.78	0.63	0.38	-0.26	0.32	0.37	0.14
Intangible Assets	0.64	0.67	0.41	-0.3	0.3	0.23	0.57	0.53	0.35	0.4	-0.07	0.51	-0.55	-0.04		0.76	0.45	-0.16	0.0	-0.52	0.27	-0.32	-0.53	-0.03
Common Stock	0.83	0.77	0.36	-0.5	0.6	0.5	0.85	0.71	0.61	0.43	0.14	0.72	-0.39	0.17	0.76		0.71	0.05	0.23	-0.41	0.38	-0.39	-0.4	-0.18
Property Plant Equipment	0.88	0.86	-0.33	0.03	0.64	0.83	0.84	0.95	0.59	0.09	0.36	0.52	0.17	0.4	0.45	0.71		0.19	0.32	0.18	-0.17	0.17	0.17	0.09
Current Deferred Revenue	0.25	-0.05	-0.34	-0.08	0.6	0.57	0.36	0.13	0.67	0.43	0.8	0.49	0.47	0.78	-0.16	0.05	0.19		0.74	0.61	-0.42	0.54	0.62	0.23
Net Debt	0.37	0.04	-0.31	-0.11	0.55	0.55	0.54	0.31	0.81	0.44	0.65	0.44	0.23	0.63	0.0	0.23	0.32	0.74		0.39	-0.26	0.35	0.37	0.17
Long Term Debt Total	0.07	-0.06	-0.85	0.56	0.3	0.57	0.06	0.16	0.26	-0.22	0.38	0.07	0.87	0.38	-0.52	-0.41	0.18	0.61	0.39		-0.71	0.83	0.98	0.29
Capital Surpluse	-0.17	-0.1	0.54	-0.8	-0.3	-0.44	-0.09	-0.25	-0.22	0.47	-0.26	-0.11	-0.79	-0.26	0.27	0.38	-0.17	-0.42	-0.26	-0.71		-0.96	-0.79	-0.7
Net Invested Capital	0.17	0.07	-0.64	0.78	0.33	0.51	0.11	0.23	0.28	-0.35	0.32	0.15	0.84	0.32	-0.32	-0.39	0.17	0.54	0.35	0.83	-0.96		0.9	0.69
Net Working Capital	0.09	-0.03	-0.78	0.62	0.35	0.57	0.07	0.18	0.28	-0.29	0.37	0.12	0.91	0.37	-0.53	-0.4	0.17	0.62	0.37	0.98	-0.79	0.9		0.4
Capital Stock	0.16	0.14	-0.15	0.69	0.14	0.19	0.11	0.17	0.13	-0.22	0.13	0.12	0.42	0.14	-0.03	-0.18	0.09	0.23	0.17	0.29	-0.7	0.69	0.4

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Avanos Medical

Ebitda Over Time

Avanos Ebitda

Ebitda

(328.32 Million)

At this time, Avanos Medical's EBITDA is comparatively stable compared to the past year.

According to the company disclosure, Avanos Medical reported earnings before interest,tax, depreciation and amortization of (345.6 Million). This is 139.39% lower than that of the Health Care Equipment & Supplies sector and 153.79% lower than that of the Health Care industry. The ebitda for all United States stocks is 108.86% higher than that of the company.

Avanos EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Avanos Medical's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Avanos Medical could also be used in its relative valuation, which is a method of valuing Avanos Medical by comparing valuation metrics of similar companies.

Avanos Medical is currently under evaluation in ebitda category among its peers.

Avanos Medical ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Avanos Medical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Avanos Medical's managers, analysts, and investors.

Environmental

Governance

Social

Avanos Medical Institutional Holders

Institutional Holdings refers to the ownership stake in Avanos Medical that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Avanos Medical's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Avanos Medical's value.

		Shares
Neuberger Berman Group Llc	2024-12-31	977.4 K
Tributary Capital Management, Llc	2024-12-31	893 K
Prudential Financial Inc	2024-12-31	570.3 K
Royal Bank Of Canada	2024-12-31	535.2 K
Northern Trust Corp	2024-12-31	526.8 K
Morgan Stanley - Brokerage Accounts	2024-12-31	502 K
D. E. Shaw & Co Lp	2024-12-31	494.6 K
Charles Schwab Investment Management Inc	2024-12-31	460 K
Amvescap Plc.	2024-12-31	363.7 K
Blackrock Inc	2024-12-31	7.2 M
Vanguard Group Inc	2024-12-31	5.3 M

Avanos Fundamentals

	Return On Equity	-0.37
	Return On Asset	0.0197
	Profit Margin	(0.57) %
	Operating Margin	0.05 %
	Current Valuation	727.71 M
	Shares Outstanding	46 M
	Shares Owned By Insiders	2.98 %
	Shares Owned By Institutions	95.94 %
	Number Of Shares Shorted	888.74 K
	Price To Earning	51.23 X
	Price To Book	0.80 X
	Price To Sales	0.97 X
	Revenue	687.8 M
	Gross Profit	381.3 M
	EBITDA	(345.6 M)
	Net Income	(392.1 M)
	Cash And Equivalents	106.5 M
	Cash Per Share	2.26 X
	Total Debt	170.2 M
	Debt To Equity	0.24 %
	Current Ratio	2.89 X
	Book Value Per Share	18.03 X
	Cash Flow From Operations	100.7 M
	Short Ratio	2.02 X
	Earnings Per Share	(8.40) X
	Price To Earnings To Growth	2.29 X
	Target Price	17.0
	Number Of Employees	2.23 K
	Beta	1.17
	Market Capitalization	665.21 M
	Total Asset	1.15 B
	Retained Earnings	(707 M)
	Working Capital	227.5 M
	Current Asset	773.54 M
	Current Liabilities	415.63 M
	Net Asset	1.15 B

About Avanos Medical Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Avanos Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avanos Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avanos Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Avanos Stock Analysis

When running Avanos Medical's price analysis, check to measure Avanos Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avanos Medical is operating at the current time. Most of Avanos Medical's value examination focuses on studying past and present price action to predict the probability of Avanos Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avanos Medical's price. Additionally, you may evaluate how the addition of Avanos Medical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC